APA

Parks D. A., Jennings H. C., Taylor C., Pakes G. E. & Acosta E. P. (20091015). Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). : HIV clinical trials.

Chicago

Parks David A, Jennings H Clay, Taylor Christopher, Pakes Gary E and Acosta Edward P. 20091015. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). : HIV clinical trials.

Harvard

Parks D. A., Jennings H. C., Taylor C., Pakes G. E. and Acosta E. P. (20091015). Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). : HIV clinical trials.

MLA

Parks David A, Jennings H Clay, Taylor Christopher, Pakes Gary E and Acosta Edward P. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). : HIV clinical trials. 20091015.